

U.S.S.N. 09/101,413
Filed: August 7, 1998

CLEAN VERSION OF AMENDMENTS PURSUANT TO 37 C.F.R. § 1.121



RECEIVED
FEB 13 2003
TECH CENTER 1600/2900

Clean Version of Amended Claims
Pursuant to 37 C.F.R. § 1.121(c)(1)(ii)

- 91
1. (Six times amended) A method of killing cells in a patient, the method comprising,

administering to the patient a therapeutically effective amount of cytotoxic T lymphocytes (CTL),

wherein the CTLs have a different HLA class I complex (or equivalent) than the cells to be killed, and

the CTLs specifically recognize a peptide portion on the cells to be killed of an antigen which is abnormally elevated in the patient, when the peptide is presented by the HLA class I complex (or equivalent) on the surface of cells to be killed, wherein the HLA class I complex (or equivalent) type presenting the peptide in the cells to be killed is not present in the CTLs to be administered to the patient, and

the CTLs kill the presenting cells.
 2. A method according to Claim 1 wherein the CTL are a clonal population of CTL.
 3. (Amended) A method according to Claim 1 wherein the CTL are substantially free of other cell types.
 6. (Three amended) A method according to Claim 1 wherein the antigen is present at an abnormally elevated amount in the cells to be killed compared to other cells.
 7. (Twice Amended) A method according to Claim 1 wherein the cells to be killed are cancer cells.

8. A method according to Claim 7 wherein the cancer is any one of breast cancer; bladder cancer; lung cancer; prostate cancer; thyroid cancer; leukemias and lymphomas such as CML, ALL, AML, PML; colon cancer; glioma; seminoma; liver cancer; pancreatic cancer; bladder cancer; renal cancer; cervical cancer; testicular cancer; head and neck cancer; ovarian cancer; neuroblastoma and melanoma.

14. (Amended) A method according to Claim 1 further comprising the step of determining the HLA class I (or equivalent) molecule type of the patient prior to administration of the CTL.

15. (Amended) A method according to Claim 14 wherein the type is determined using DNA typing.

16. (Amended) A method according to Claim 1 wherein the patient is human.

17. (Twice Amended) A method according to Claim 14 wherein the cytotoxic T lymphocyte is selected from a library of CTL clones, the library comprising a plurality of CTL clones derived from individuals with differing HLA class I (or equivalent) molecule type and each CTL clone recognises the cells to be killed.

18. (Twice Amended) A method according to Claim 17 wherein each CTL clone recognizes at least part of the same molecule contained in or associated with the cells to be killed.

g2 27. (Four times amended) A method according to claim 1 wherein the antigen is selected from the group consisting of cyclin D1, cyclin E, mdm 2, EGF-R, erb-B2, erb-B3, FGF-

U.S.S.N. 09/101,413

Filed: August 7, 1998

CLEAN VERSION OF AMENDMENTS PURSUANT TO 37 C.F.R. § 1.121

gs R, insulin-like growth factor receptor, Met, myc, a p53, BCL-2, a polypeptide associated with the BCR/ABL translocation in CML and ALL, a CSF-1 receptor, an APC, a RET, an EGFR, a polypeptide associated with PML/RARA translocation in PML, and a polypeptide associated with E2A-PBX1 translocation in pre B leukaemias and in childhood acute leukaemias.
